KR100912912B1 - Herbal composition for relieving and treating primary dysmenorrhea - Google Patents
Herbal composition for relieving and treating primary dysmenorrhea Download PDFInfo
- Publication number
- KR100912912B1 KR100912912B1 KR1020070031630A KR20070031630A KR100912912B1 KR 100912912 B1 KR100912912 B1 KR 100912912B1 KR 1020070031630 A KR1020070031630 A KR 1020070031630A KR 20070031630 A KR20070031630 A KR 20070031630A KR 100912912 B1 KR100912912 B1 KR 100912912B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- pain
- herbal composition
- primary dysmenorrhea
- herbal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 31
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 7
- 229940010454 licorice Drugs 0.000 claims abstract description 7
- 235000017788 Cydonia oblonga Nutrition 0.000 claims abstract description 6
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 6
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 6
- 210000004207 dermis Anatomy 0.000 claims abstract description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000003809 water extraction Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 27
- 208000024891 symptom Diseases 0.000 abstract description 19
- 208000002193 Pain Diseases 0.000 abstract description 16
- 241000411851 herbal medicine Species 0.000 abstract description 13
- 206010019233 Headaches Diseases 0.000 abstract description 7
- 231100000869 headache Toxicity 0.000 abstract description 7
- 208000008035 Back Pain Diseases 0.000 abstract description 6
- 210000001015 abdomen Anatomy 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 3
- 240000006054 Agastache cana Species 0.000 abstract description 2
- 244000080767 Areca catechu Species 0.000 abstract description 2
- 235000006226 Areca catechu Nutrition 0.000 abstract description 2
- 235000010650 Hyssopus officinalis Nutrition 0.000 abstract description 2
- 206010042674 Swelling Diseases 0.000 abstract description 2
- 230000009471 action Effects 0.000 description 14
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 12
- 230000005906 menstruation Effects 0.000 description 11
- 230000000144 pharmacologic effect Effects 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- RTBLDXVIGWSICW-JMSVASOKSA-N (1R,7R,10R)-4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-ene Chemical compound C[C@@H]1CC[C@@H]2CC3=C(C)CC[C@]13C2(C)C RTBLDXVIGWSICW-JMSVASOKSA-N 0.000 description 2
- DNJFTXKSFAMXQF-UHFFFAOYSA-N Arecaidine Chemical compound CN1CCC=C(C(O)=O)C1 DNJFTXKSFAMXQF-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 239000008589 Cortex Fraxini Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 240000008154 Piper betle Species 0.000 description 2
- 235000008180 Piper betle Nutrition 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- 241000133134 Saussurea Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- QTDZOWFRBNTPQR-UHFFFAOYSA-N guvacine Chemical compound OC(=O)C1=CCCNC1 QTDZOWFRBNTPQR-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 231100000551 menstrual abnormality Toxicity 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- -1 C 28 H 34 O 15 ) Chemical compound 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- APWLDLGOYJHNIK-YUELXQCFSA-N Cyperol Chemical compound C1C[C@@H](O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C APWLDLGOYJHNIK-YUELXQCFSA-N 0.000 description 1
- APWLDLGOYJHNIK-CFVMTHIKSA-N Cyperol Natural products O[C@H]1C(C)=C2[C@](C)(CC1)CC[C@H](C(=C)C)C2 APWLDLGOYJHNIK-CFVMTHIKSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000251905 Pseudocydonia sinensis Species 0.000 description 1
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008345 muscle blood flow Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000009536 samultang Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 원발성 생리통 완화 및 치료용 한약조성물에 관한 것으로, 귀전우, 계지, 의이인, 창출, 향부자, 진피, 우슬, 모과, 빈랑, 강활, 회향, 목향, 감초 및 부자를 포함하는 총 14종의 한방재를 함유함으로써, 대부분의 생리통 환자에게서 나타나는 아랫배 통증, 허리 통증, 부종, 두통 등의 생리통 증상을 우수하게 치료할 수 있다.The present invention relates to a herbal composition for relieving and treating primary dysmenorrhea, and includes a total of 14 kinds including woowoo, gyeji, uiyiin, creation, hyangbuja, dermis, hyssop, quince, betel nut, vigor, fennel, scented, licorice and rich By containing the herbal medicine, it is possible to treat the symptoms of menstrual pain such as belly pain, back pain, swelling, and headache, which appear in most menstrual pain patients.
생리통, 한약 조성물, 한방재, 생약, 귀전우 Menstrual pain, herbal composition, herbal medicine, herbal medicine, ear cow
Description
도 1은 본 발명의 한약조성물을 복용한 보통체형인의 복용기간에 따른 생리통증 변화를 나타낸 그래프이다.1 is a graph showing the change in menstrual pain according to the period of administration of the normal body type taking the herbal composition of the present invention.
도 2는 본 발명의 한약조성물을 복용한 비만체형인의 복용기간에 따른 생리통증 변화를 나타낸 그래프이다.Figure 2 is a graph showing the change in menstrual pain in accordance with the duration of the obese body type taking the herbal composition of the present invention.
본 발명은 원발성 생리통 완화 및 치료용 한약조성물에 관한 것으로, 보다 상세하게는 원발성 생리통 환자의 생리 전이나 생리기간 동안 발생하는 생리통을 완화 및 치료하는 한약조성물에 관한 것이다.The present invention relates to a herbal composition for alleviating and treating primary dysmenorrhea, and more particularly, to a herbal composition for alleviating and treating dysmenorrhea occurring before or during menstruation of a primary dysmenorrhea patient.
생리통은 사춘기가 지난 여성의 약 50%가 경험하는 가장 흔한 부인과 질병으로서, 그중 약 10 내지 15%의 여성은 매달 1 내지 3일 동안 일상생활을 하기 힘들 정도의 통증을 느끼게 된다. 이로 인해, 생리통은 젊은 여성들이 직장 또는 학교를 쉬게 되는 주요 원인이 되고 있으며 작업시간의 손실이나 학습장애를 일으킨다.Menstrual pain is the most common gynecological disease experienced by about 50% of women after puberty, of which about 10 to 15% of women experience pain that is difficult for daily life for one to three days each month. As a result, menstrual cramps are a major cause for young women to leave work or school and cause loss of working time or learning disabilities.
생리통은 그 원인에 따라 크게 원발성(1차성) 생리통과 속발성(2차성) 생리 통으로 분류된다. 원발성 생리통은 골반이나 자궁내에 특별한 병변없이 발생하는 체질적인 생리통으로, 대부분의 생리통이 이에 해당한다. '프로스타글란딘(prostaglandin)'이라는 호르몬이 과다분비되어 자궁수축이 항진되어 나타나는 현상으로서, 한의학적인 측면은 통하지 않기 때문에 압력이 높아져서 통증이 발생한다는 '불통 즉 통(不通則痛)'으로 인식하고 있다. 보통의 경우 그 통증은 생리를 시작하기 수 시간 전이나 시작한 직후부터 시작되어 2~3일간 증세가 지속된다. 방광위쪽에서 진통과 비슷한 양상으로 느껴지며, 허리 및 천골 통증과 허벅지까지 통증이 전파될 수 있고, 오심 및 구토와 함께 설사를 동반할 수도 있다. 한편, 속발성 생리통은 자궁이나 주위 장기에 특별한 병변이 생겨서 발생하는 통증으로서, 그 원인이 되는 병변으로는 자궁근종, 자궁선근종, 자궁내막증, 난소낭종, 골반염, 골반유착, 자궁내 피임장치, 종양 등이 있다. 그 통증은 초경이 지난 몇년 후에 이러한 병변이 발생함에 따라 나타나는데, 통증이 생리 시작 1~2주전부터 나타나기 시작하여 생리가 끝난 이후에도 며칠간 지속된다는 점이 원발성 생리통과 다른 특징이다.Menstrual pain is classified into primary (primary) dysmenorrhea and secondary (secondary) dysmenorrhea depending on the cause. Primary dysmenorrhea is a constitution that occurs without any special lesions in the pelvis or uterus. As "prostaglandin (prostaglandin), developing hormone is secreted over-represented is enhancing the uterine contractions that, TCM side is recognized as" tweaked i.e. barrel (不通則痛), that the high and the pressure pain occurs because the work. Usually, the pain begins several hours before or shortly after menstruation and lasts for two to three days. It feels like pain relief in the upper bladder, and pain can spread to lower back and sacral pain and thighs, and may be accompanied by diarrhea with nausea and vomiting. On the other hand, secondary dysmenorrhea is a pain caused by the development of a special lesion in the uterus or surrounding organs. The causes of the lesion include uterine myoma, uterine adenoma, endometriosis, ovarian cyst, pelvic inflammation, pelvic adhesion, intrauterine contraceptive device, tumor, etc. There is this. The pain manifests itself as the lesion develops in the last few years after menarche, which is different from primary dysmenorrhea in that it begins to appear one to two weeks before the start of menstruation and lasts for several days after the end of menstruation.
일반적으로, 자궁은 생리주기에 따라 자궁수축의 강도가 다르다. 생리통이 없는 정상인의 경우, 생리 중에는 분만시와 같은 과도한 자궁수축이 일어나므로 자궁내 압력이 100㎜Hg 이상으로 상승하기도 하고, 증식기에는 자궁수축의 강도와 빈도가 떨어져 자궁내 압력이 약 10~30㎜Hg를 나타내며, 황체기에는 자궁내 압력이 60~90㎜Hg 정도로 약간 증가하여 생리 수일 전에는 분만의 시작 전과 비슷한 자궁수축이 일어난다. 비배란주기, 즉, 프로게스테론(progesterone)이 부족한 경우에 는 증식기와 비슷한 자궁수축만을 나타낸다. 그러나, 원발성 생리통 환자는 정상인에 비하여 자궁수축이 지속되는 시간이 길며, 자궁수축이 없는 동안의 자궁내 압력 또한 더 높고, 수축시에는 자궁내 압력이 약 200~300㎜Hg까지 상승하기도 한다. 이러한 과도한 자궁수축으로 자궁으로의 혈류공급이 줄어들어 자궁내에 빈혈이 초래되어 원발성 생리통이 나타나게 되는 것으로 여겨진다.In general, the uterus has a different intensity of uterine contractions depending on the menstrual cycle. In normal people without dysmenorrhea, excessive uterine contractions occur during menstruation, so intrauterine pressure may increase to 100 mmHg or more. In luteal phase, intrauterine pressure increases slightly to 60-90 mmHg, and uterine contractions occur before menstruation a few days before menstruation. Non-ovulation cycles, ie, lack of progesterone, show only uterine contractions similar to the proliferative phase. However, patients with primary dysmenorrhea have a longer duration of uterine contraction than normal people, higher intrauterine pressure during the absence of uterine contraction, and intrauterine pressure may increase to 200-300 mmHg during contraction. This excessive uterine contraction reduces the blood supply to the uterus, resulting in anemia in the uterus, which is believed to result in primary dysmenorrhea.
생리통의 대부분을 차지하는 원발성 생리통의 완화 및 치료 요법으로는 하복부를 따뜻하게 하고 차가운 음식은 피하며 가벼운 운동을 하고 몸의 혈액순환을 돕는 따뜻한 샤워를 하는 대증요법(對症療法), 프로스타글란딘 억제제를 투여하는 방법, 배란을 억제하여 무배란 상태를 유지하는 에스트로겐(estrogen) 요법, 프로게스테론(progesterone) 요법, 테스트로스테론(testrosterone) 요법, 자궁수축 억제제를 투여하는 방법 등이 널리 알려져 있다. 이들 중 가장 보편적으로는 프로스타글란딘의 합성을 방해하는 진통제(아스피린계가 대표적)를 복용하여 치료하는 방법이 이용되고 있지만, 아스피린 계통의 약물에 알레르기가 있거나 위궤양이 있는 사람은 이를 사용할 수 없으며, 진통제에 너무 의존하거나 장기복용하면 부작용이 따를 수 있어 바람직하지 못하다.Relief and treatment of primary dysmenorrhea, which accounts for the majority of dysmenorrhea, is a symptomatic treatment of warming the lower abdomen, avoiding cold foods, exercising lightly, taking a warm shower to help the body's blood circulation, and administering prostaglandin inhibitors. Estrogen therapy, progesterone therapy, testrosterone therapy, uterine contraction inhibitors, and the like are widely known. The most common of these is the treatment of taking analgesics (aspirin is typical) that interfere with the synthesis of prostaglandins, but those who are allergic to aspirin drugs or have gastric ulcers cannot use them, and they are too much for painkillers. Dependence or long-term use is undesirable because it can have side effects.
한편, 한의학에서는 생리통 치료를 위하여 당귀수산(當歸鬚散), 만통환, 월통환 등을 사물탕(四物湯)에 가미하여 사용하여 왔다. 한약재를 이용한 생리통의 또 다른 치료법에 관한 연구가 다양하게 진행되고 있다. 한국특허공개 제10-2005-4950호에는 복합생약을 함유한 생리통 및 월경불순 예방 및 치료용 조성물에 관한 것으로, 이를 위하여 향부자, 당귀, 봉출, 목단피, 애엽, 오약, 천궁, 현호색, 삼 릉, 시호, 홍화 및 오매의 복합추출물을 사용하고 있다.On the other hand, in oriental medicine, Dangguisu (當歸 鬚 散), Mantonghwan, Woltonghwan, etc. have been used in Samultang for the treatment of menstrual pain. There are various researches on another treatment method for menstrual pain using herbal medicine. Korean Patent Publication No. 10-2005-4950 relates to a composition for preventing and treating menstrual cramps and menstrual impurities containing complex herbal medicines. Shiho, safflower and omae complex extracts are used.
앞서 알려진 복합 생약재를 사용하는 방법에 한정되지 않고, 다양한 생약재를 적절히 혼합하여 사용할 경우 자궁수축 지속시간을 줄이고, 자궁수축이 없는 동안의 자궁내 압력과 수축시 자궁내 압력을 낮출 수 있어 원발성 생리통 완화 및 치료에 더욱 우수한 효과를 나타내는 한약조성물을 제조할 수 있을 것이라 기대된다.It is not limited to the method of using the previously known complex herbal medicines, and by mixing various herbal medicines properly, the duration of uterine contraction can be reduced, the intrauterine pressure during uterine contraction and the intrauterine pressure during contraction can be alleviated. And it is expected to be able to manufacture a herbal composition showing a more excellent effect on the treatment.
본 발명자는 한방재로 사용되고 있는 다양한 생약재를 대상으로 연구를 거듭한 결과, 현재까지 생리통 처방을 위해 사용된 적이 없는 귀전우를 포함하여 총 14종의 한방재를 포함하는 본 발명의 한약조성물을 사용할 경우 원발성 생리통의 완화 및 치료에 우수한 효과를 나타냄을 발견하고 본 발명을 완성하게 되었다.The present inventors have conducted research on various herbal medicines that are used as herbal medicine, and as a result, the herbal composition of the present invention including a total of 14 kinds of herbal medicines, including ear cows, which have not been used for prescription menstrual pain until now, can be used. The present invention has been found to have an excellent effect on the alleviation and treatment of primary dysmenorrhea.
본 발명의 목적은 원발성 생리통을 완화 및 치료할 수 있는 한약조성물을 제공하는 것이다.An object of the present invention is to provide a herbal composition that can alleviate and treat primary dysmenorrhea.
이러한 목적을 달성하기 위하여 본 발명에 따른 원발성 생리통 완화 및 치료용 한약조성물은, 조성물 총 중량에 대하여 계지 10 내지 12중량%, 의이인 10 내지 12중량%, 창출 7 내지 9중량%, 향부자 5 내지 7중량%, 진피 5 내지 7중량%, 우슬 5 내지 6중량%, 모과 5 내지 7중량%, 빈랑 5 내지 7중량%, 강활 5 내지 7중량%, 회향 5 내지 7중량%, 목향 5 내지 7중량%, 감초 5 내지 7중량%, 부자 3 내지 4중량% 및 잔량으로서 귀전우를 포함하도록 이루어진다.In order to achieve the above object, the herbal composition for relieving and treating primary dysmenorrhea in accordance with the present invention is 10 to 12% by weight, 10 to 12% by weight, 7 to 9% by weight, 7 to 9% by weight, hyangbuja 5 to 7 based on the total weight of the composition 5% to 5% by weight, dermis 5 to 7% by weight, 5 to 6% by weight of quince, 5 to 7% by weight of quince, 5 to 7% by weight of betel nuts, 5 to 7% by weight of fennel, 5 to 7% by weight of fennel %, Licorice 5 to 7% by weight, rich 3 to 4% by weight and the balance is made to include the ear cow.
이하, 본 발명을 좀 더 구체적으로 설명하면 다음과 같다.Hereinafter, the present invention will be described in more detail.
본 발명에 따른 원발성 생리통 치료용 한약조성물은 귀전우(鬼箭羽; Ramulus Euonymi), 계지(桂枝; Ramulus Cinnamomi), 의이인(薏苡仁; Semen Coicis), 창출(蒼朮; Rhizoma Atractylodis japonicae), 향부자(香附子; Rhizoma Cyperi), 진피(陳皮; Cortex Fraxini), 우슬(牛膝; Radix Achyranthis Bidentatae), 모과(木瓜; Fructus Chaenomelis), 빈랑(Semen Arecae), 강활(羌活; Rhizoma Seu Radix Notopterygh), 회향(茴香; Fructus Foeniculi), 목향(木香; Radix Saussurea Seu Inulae), 감초(甘草; Radix Glycyrrhizae) 및 부자(附子; Radix Aconiti Lateralis Preparata)를 포함하여 이루어짐을 특징으로 한다. 본 발명은 역대문헌과 현재 쓰이고 있는 70여 가지의 생리통 치료용 처방 어디에도 쓰이지 않는 '귀전우'가 대표약으로 사용되었고, 불통(不通)의 원인이 되는 습(濕)을 없애고 돌려주는 '의이인' 및 '창출'이 포함되며, 생리통 처방 중 시호정향탕(柴胡丁香湯)에만 들어가는 '강활'이 포함된다는 점에 가장 큰 특징이 있으며, 원발성 생리통 치료 효과 또한 탁월하다.Herbal compositions for treating primary dysmenorrhea in accordance with the present invention include: Ramulus Euonymi, Ramulus Cinnamomi, Semen Coicis, Rhizoma Atractylodis japonicae, Hyangbuja (附) Rhizoma Cyperi, Cortex Fraxini, Radix Achyranthis Bidentatae, Fructus Chaenomelis, Semen Arecae, Rhizoma Seu Radix Notopterygh, Fructus Foeniculi, Mox (Radix Saussurea Seu Inulae), Licorice (Radix Glycyrrhizae) and Rich (Radix Aconiti Lateralis Preparata). The present invention was used as a representative medicine 'purewoowoo' which is not used anywhere in the past literature and 70 kinds of prescription for treating menstrual pain, and 'uiyiin' that removes and returns the dampness causing the discomfort. And 'creation', and the most characteristic is that the 'active' that only goes to Shihojeonghyangtang (柴胡 丁香 湯) of the prescription of menstrual pain is included, and the primary menstrual pain treatment effect is also excellent.
이들 성분 중 귀전우(鬼箭羽; Ramulus Euonymi)는 생리이상, 타박상, 산후복통 등의 병증을 치료하며, 약리작용으로 심박동이상, 진정작용, 혈압강하작용, 혈당강하작용, 관상동맥혈류량 증가, 장관수축작용 등이 보고되었다. 이밖에 최근에 와서는 임상에서 간암과 자궁경부암의 치료에도 응용하고 있다.Among these components, Ramulus Euonymi treats symptoms such as menstrual disorders, bruises, postpartum abdominal pain, etc., and pharmacological actions include cardiac abnormalities, sedation, blood pressure lowering, hypoglycemic action, increased coronary blood flow, Intestinal contraction has been reported. In recent years, clinical applications have been applied to the treatment of liver and cervical cancer.
계지(桂枝; Ramulus Cinnamomi)는 주성분이 시나몬알데히드(cinnamon aldehyde 약 85%)로서 피부표면의 발한 등을 제어하고 진통작용이 있어 생리통 및 생리 이상, 찬바람을 많이 쐬어서 생기는 감기, 식은 땀 등의 병증을 치료한다. 약리작용은 대장군, 고초간균, 황색포도균, 폐렴쌍구균 등의 발육을 억제하고 유행성 감기바이러스를 억제하며 이뇨작용 등이 보고되었다.Ramulus Cinnamomi is the main ingredient of cinnamon aldehyde (cinnamon aldehyde about 85%) to control sweating on the surface of the skin and has analgesic effects such as menstrual pain, menstrual abnormalities, cold wind caused by a lot of cold wind, cold sweat, etc. Treat the condition Pharmacological action has been reported to inhibit the development of E. coli, Bacillus subtilis, Staphylococcus aureus, Pneumococcal pneumoniae, inhibits pandemic flu virus, and diuretic effect.
의이인(薏苡仁; Semen Coicis)은 타 곡류에 비해 루이신(leucine), 티로신(tyrosine) 등의 단백질이 풍부하고, 글루타민산(glutamin)이 적다. 수종, 각기, 소화불량으로 소변이 잘 나오지 않는 증상, 설사, 식욕부진 등의 치료에 쓰인다. 사지마비, 동통, 굴신불리와 근육통, 해열, 배농, 맹장염 등에도 사용한다. 약리작용은 항암, 골격근수축억제, 장관자궁억제, 진정, 진통 및 해열작용이 보고되었다.Semen Coicis is rich in proteins such as leucine and tyrosine and less glutamin than other grains. It is used to treat the symptoms of diarrhea, diarrhea, and loss of appetite due to species, indigestion and indigestion. It is also used for quadriplegia, pain, flexing and muscle aches, fever, drainage, appendicitis. Pharmacological action has been reported to be anti-cancer, skeletal muscle contraction suppression, intestinal uterus suppression, soothing, analgesic and antipyretic effect.
창출(蒼朮; Rhizoma Atractylodis japonicae)은 그 주성분으로서 아트락티롤(Atractylol; C15H24O), 아트락티론(Atractylon; C14H18O), 비타민 A, 비타민 D 등을 포함한다. 소화기능을 강하게 하고 비정상적인 체액을 걸러내고 시력을 좋게 하여 복부팽만, 설사, 수종, 각기, 밤눈이 어두운 증상 등을 치료한다.Rhizoma Atractylodis japonicae includes, as its main component, atacticulol (Atractylol; C 15 H 24 O), attractyllon (C 14 H 18 O), vitamin A, vitamin D and the like. It strengthens digestive function, filters out abnormal body fluids and improves eyesight to treat abdominal distension, diarrhea, edema, each one, and dark eyes at night.
향부자(香附子; Rhizoma Cyperi)는 그 주성분으로서 사이페린(Cyperene; 약 37%) 및 사이페롤(Cyperol; 약 48%)을 포함하며, 생리를 조절하고 폐결핵, 늑간부 동통, 생리통 등을 치료한다.Rhizoma Cyperi, the main ingredient, contains Cyperene (about 37%) and Cyperol (about 48%), regulates menstruation, treats pulmonary tuberculosis, intercostal pain, dysmenorrhea, etc. .
진피(陳皮; Cortex Fraxini)는 휘발성정유, 배당체(헤스페레딘; Hesperidin, C28H34O15), 구연산 등을 포함하며, 기가 뭉친 것을 풀어주고 비장의 기능을 강화하여 복부창만, 트림, 구토, 메스꺼움, 소화불량, 헛배가 부르고 나른한 증상, 대변이 묽은 증상 등을 치료한다. 약리작용은 정유 성분이 소화기 자극, 소화 촉진, 거담, 항궤양, 항위액분비, 강심, 혈압상승, 항알레르기, 담즙분비촉진, 자궁평활근억제, 항균작용 등을 하는 것으로 보고되었다.Cortex Fraxini contains volatile essential oils, glycosides (Hesperidin, C 28 H 34 O 15 ), citric acid, etc. Treat nausea, indigestion, flatulence, drowsiness, and stool diarrhea. Pharmacological action has been reported that essential oils have digestive stimulation, digestive stimulation, expectorant, anti-ulcer, antigastric secretion, cardiac, blood pressure increase, antiallergic, bile secretion, uterine smooth muscle suppression, antibacterial action.
우슬(牛膝; Radix Achyranthis Bidentatae)은 사포닌, 칼륨, 점액질 등을 함유하였으며, 혈액순환과 관절영양 등의 작용이 있어 월경이상, 산후복통, 관절통, 토혈 등을 치료한다. 약리작용으로 자궁흥분작용, 콜레스테롤 강하작용, 이뇨작용, 혈당강하작용, 간기능 개선작용 등이 보고되었다.Radix Achyranthis Bidentatae contains saponin, potassium, mucus, etc. It has blood circulation and joint nutrition to treat menstrual abnormalities, postpartum abdominal pain, joint pain and hemorrhage. As pharmacological action, uterine excitement, cholesterol lowering action, diuretic action, hypoglycemic action, liver function improvement action, etc. have been reported.
모과(木瓜; Fructus Chaenomelis)는 시트르산, 비타민 C 등을 함유하였으며, 사지마비통증, 근육이 굴신이 되지 않을 때, 하체마비경련, 근육이 땅겨서 목이 돌아가지 않을 때, 각기병, 토사곽란, 소화불량 등에 사용한다. 약리작용으로 단백성관절염, 부종억제작용, 복수암억제작용, 추간판탈축증 완화작용 등이 보고되었다.Chinese quince Fructus Chaenomelis contains citric acid, vitamin C, etc., and has quadriplegia pain, muscle flexion, lower extremity cramps, muscle stiffness, and sore throat. Used for As pharmacological actions, proteomic arthritis, edema suppression, ascites cancer suppression, intervertebral pharyngeal alleviation and the like have been reported.
빈랑(Semen Arecae)은 타닌과 중요 알칼로이드로서 아레카이딘(Arecaidine), 아레콜린(Arecoline), 구바신(guvacine), 구바콜린(guavacoline) 등을 함유하고 있으며, 촌충구제, 설사, 피부병, 두통 등에 사용한다.Semen Arecae contains tannins and important alkaloids such as Arecaidine, Arecoline, Guvacine, Guavacoline, etc., used for tapeworms, diarrhea, skin diseases, headaches, etc. do.
강활(羌活; Rhizoma Seu Radix Notopterygh)은 발산작용이 강하여 외감성 두통, 오한, 발열 등에 쓰고, 관절통, 근육경련마비, 견갑배통, 구안화사, 피부궤양 및 창진, 초기의 오한, 발열, 동통 등에 사용한다. 약리작용으로 해열, 진통, 피부진균 억제, 심장 근육 혈류량 증가작용 등이 보고되었다.Rhizoma Seu Radix Notopterygh has strong divergence and is used for external headache, chills and fever, joint pain, muscle spasms, scapula pain, guanhwasa, skin ulcers and swelling, early chills, fever and pain. . Pharmacological actions have been reported for antipyretic, analgesic, skin fungal inhibition, cardiac muscle blood flow.
회향(茴香; Fructus Foeniculi)은 정유 3~8%를 함유하고, 그 주성분으로서 아네톨(anethole; C10H12O, 50~60%), 지방유 등을 포함한다. 몸을 따뜻하게 하고, 통증 억제, 소화기 강화 등의 효능이 있어 부인과질환, 소화불량 등에 요긴하게 쓰인다.Fructus Foeniculi contains 3-8% of essential oils and includes anethole (C 10 H 12 O, 50-60%), fatty oil, and the like as its main components. It warms the body, suppresses pain and strengthens the digestive system, so it is useful for gynecological diseases and indigestion.
목향(木香; Radix Saussurea Seu Inulae)은 복부가 차서 생기는 복통, 헛배 부른 증상, 구토, 설사 등에 사용하며, 기를 잘 통하게 해 소화기의 만성 염증, 위통에 효과가 있고, 항균작용이 있어서 이질과 고환염에 쓰인다. 약리작용으로 기관지와 소장 경련을 풀어 주며, 혈압강하작용, 항균작용 등이 보고되었다.Mokhyang (木香) Radix Saussurea Seu Inulae is used for abdominal pain, flat stomach, vomiting and diarrhea caused by cold abdomen. Used for Pharmacological action to release bronchial and small intestine spasms, blood pressure lowering action, antibacterial action has been reported.
감초(甘草; Radix Glycyrrhizae)는 주성분으로서 글리치리친(C42H66O18), 기타 리키리틴(Liquirtin; C21H22O9), 만니트, 아스파라긴 등을 포함한다. 모든 약의 독성을 조화시켜서 약효가 잘 나타나게 하며, 장부의 한열과 사기를 다스리고 모든 혈맥의 소통을 잘 시키며 근육과 뼈를 튼튼히 한다. 진해, 거담, 근육이완, 이뇨작용, 항염작용이 있으며 소화성 궤양을 억제한다. 약리작용은 해독작용, 간염, 두드러기, 피부염, 습진 등이 보고되었다.Licorice (Radix Glycyrrhizae) contains Glycrichine (C 42 H 66 O 18 ), Other Liquirtin (C 21 H 22 O 9 ), Mannit, Asparagine, etc. Harmonize the toxicity of all drugs to make the drug appear well, to control the heat and morale of the book and all blood vessels to communicate well and to strengthen the muscles and bones. Jinhae, expectorant, muscle relaxation, diuretic, anti-inflammatory action and suppresses peptic ulcer. Pharmacological action has been reported detoxification, hepatitis, urticaria, dermatitis, eczema.
부자(附子; Radix Aconiti Lateralis Preparata)는 아코니틴(Aconitine; C23H4NO11)을 포함하며, 뿌리의 대소 및 산지에 따라 함유성분의 양과 질이 상이하다. 신장의 양기를 보하고 강심작용이 있어 각종 만성질환에 따른 양기 쇠약, 전신과 사지관절마비, 냉감, 만성궤양, 곽란, 설사 등에 쓰인다. 약리작용으로 심장근육수축, 혈압상승, 항염, 진통, 항한랭작용, 면역증강작용, 뇌하수체 및 부신피질 흥분작용, 혈당강하작용 등이 보고되었다.Radix Aconiti Lateralis Preparata (Acicotine) contains aconitine (C 23 H 4 NO 11 ) and varies in amount and quality depending on the size and origin of roots. Kidney swells and has a cardiovascular effect due to various chronic diseases, weakness, systemic and limb joint paralysis, cold feeling, chronic ulcers, erosion, diarrhea, etc. are used. Pharmacological actions include cardiac muscle contraction, blood pressure rise, anti-inflammatory, analgesic, anti-cold action, immunopotentiation, pituitary and adrenal cortex excitability, and hypoglycemic action.
본 발명의 한약조성물은 조성물 총 중량에 대하여 상기 계지 10 내지 15중량%, 의이인 10 내지 15중량%, 창출 7 내지 10중량%, 향부자 5 내지 7중량%, 진피 5 내지 7중량%, 우슬 5 내지 7중량%, 모과 5 내지 7중량%, 빈랑 5 내지 7중량%, 강활 5 내지 7중량%, 회향 5 내지 7중량%, 목향 5 내지 7중량%, 감초 5 내지 7중량%, 부자 3 내지 5중량% 및 잔량으로서 귀전우를 포함하도록 이루어진다. 이들 성분은 모두 한약 제조시 사용되는 통상의 건조된 약재 형태의 것을 의미한다. 상기 각 성분이 상,하한치 범위를 벗어날 경우 원발성 생리통 환자의 과도한 자궁수축 현상을 개선시키는 효과가 크지 않아 생리통 완화 및 치료 효과가 미약하거나 없게 된다.The herbal composition of the present invention is 10 to 15% by weight, 10 to 15% by weight, 7 to 10% by weight, 5 to 7% by weight, 5 to 7% by weight, 5 to 7% by weight of dermis, 5 to 5% by weight, based on the total weight of the composition. 7 wt%, quince 5-7 wt%, betel 5-7 wt%, active 5-7 wt%, fennel 5-7 wt%, cedar 5-7 wt%, licorice 5-7 wt%, rich 3-5 And by weight percent and remainder. All of these components mean in the form of conventional dried medicinal herbs used in the manufacture of Chinese medicine. When each component is out of the upper and lower limits, the effect of improving excessive uterine contraction in primary dysmenorrhea patients is not so large that the menstrual pain relief and treatment effect is weak or absent.
상기한 조성을 갖는 본 발명의 한약조성물을 통상의 방법에 따라 열수추출하여 열수추출물을 얻을 수 있으며, 이 추출물을 동결건조하여 분말상 건조추출물을 얻을 수도 있다. 이들 추출물을 유효성분으로 포함하여 원발성 생리통을 완화하거나 치료할 수 있다. 열수추출은 100~125℃ 온도에서 2~3시간동안 하는 것이 가장 바람직하다.The herbal composition of the present invention having the composition described above can be subjected to hot water extraction according to a conventional method to obtain a hot water extract, and the extract can be lyophilized to obtain a powdery dry extract. These extracts can be included as active ingredients to alleviate or treat primary dysmenorrhea. Hot water extraction is most preferably carried out for 2 to 3 hours at a temperature of 100 ~ 125 ℃.
또한, 상기 조성을 갖는 본 발명의 한약조성물을 통상의 방법에 따라 물, 탄소수 1 내지 5의 알코올 또는 알코올 수용액으로 이루어지는 군으로부터 선택된 1종 이상의 용매를 사용하여 추출함으로써 추출액을 얻을 수 있으며, 이 추출액 또는 이를 동결건조하여 얻은 분말상 건조추출물을 원발성 생리통의 완화 및 치료를 위하여 사용할 수도 있다.In addition, the herbal composition of the present invention having the above composition can be extracted by using one or more solvents selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms or an aqueous solution of alcohol according to a conventional method, and the extract can be obtained. Powdered dry extract obtained by lyophilization may be used for the relief and treatment of primary dysmenorrhea.
이러한 본 발명의 한약조성물은 상기한 성분을 포함하여 제조되는 것이라면 그 제형에 특별한 제한이 없으며, 예를 들어, 환제, 정제, 캡슐제, 액제, 건강식품, 건강음료 등과 같은 제형을 가질 수 있다.Such a herbal composition of the present invention is not particularly limited as long as it is prepared by including the above components, for example, it may have a formulation such as pills, tablets, capsules, liquids, health foods, health drinks and the like.
이하, 제조예 및 실시예를 들어 본 발명을 상세히 설명하지만 본 발명이 이들 예로만 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to production examples and examples, but the present invention is not limited only to these examples.
<제조예 1> 한약조성물 Preparation Example 1 Herbal Medicine Composition
건조된 귀전우 200g, 계지 150g, 의이인 100g, 창출 70g, 향부자, 진피, 우슬, 모과, 빈랑, 강활, 회향, 목향 및 감초 각 50g, 부자 30g을 균일하게 혼합하여 복합 생약 분말인 한약조성물을 제조하였다.200g dried dried cow, 150g gyeuiin 100g, 70g creation, hyangbuja, dermis, hyssop, quince, betel nut, vigor, fennel, throat and licorice each 50g, rich 30g herbal medicine composition is prepared by mixing It was.
<제조예 2> 한약조성물의 열수추출물Preparation Example 2 Hot Water Extract of Herbal Composition
3차 증류수 10ℓ가 담긴 플라스크에 제조예 1의 혼합물 700g을 투입한 후, 100℃ 온도에서 2시간동안 열수추출하여 열수추출액을 얻었다. 수집된 열수추출액을 거즈로 여과하여 얻은 여액을 45℃ 온도, 1기압에서 감압여과기(Eyela사 제품, 일본 소재)로 농축하여 추출액을 분리하였다.700 g of the mixture of Preparation Example 1 was added to a flask containing 10 liters of distilled water, followed by hot water extraction at 100 ° C. for 2 hours to obtain a hot water extract. The filtrate obtained by filtering the collected hot water extract with gauze was concentrated by a vacuum filter (Eyela Co., Japan) at 45 ℃ temperature, 1 atm to separate the extract.
<시험예 1> 생리통 완화 및 치료 효능 평가<Test Example 1> alleviation of menstrual pain and evaluation of treatment efficacy
2005년 10월부터 2006년 11월까지 출원인의 한의원에 방문한 원발성 생리통을 가진 17-40세 여성 31명에게 생리 예정일 또는 생리시작일로부터 수일간 1일에 2회씩 제조예 2의 열수추출액 100㎖를 복용하도록 하였다. 복용 후 그 증상을 평 가하도록 하고, 그 결과를 하기 표 1에 나타내었다. 아랫배 통증은 31명 모두가 가진 공통 증상이었고, 허리통증은 이들 가운데 11명, 부종은 이들 가운데 5명, 그리고, 두통은 이들 가운데 4명이 호소하였다.Thirty-seven women aged 17-40 who had primary dysmenorrhea visited the applicant's oriental clinic from October 2005 to November 2006, taking 100 ml of hot water extract of Preparation Example 2 twice a day for several days from the date of menstruation or menstruation. I did it. To evaluate the symptoms after taking, the results are shown in Table 1 below. Lower abdominal pain was a common symptom in all 31 patients. Back pain was reported in 11 of them, edema in 5 of them, and headache in 4 of them.
상기 표 1로부터 알 수 있는 바와 같이, 본 발명의 한약조성물은 원발성 생리통의 주요증상에 속하는 아랫배 통증, 허리 통증, 부종 및 두통 모두에 대하여 그 완화 및 치료 효능이 우수하다.As can be seen from Table 1, the herbal composition of the present invention is excellent in alleviating and treating efficacy for all the belly pain, back pain, edema and headache belonging to the main symptoms of primary dysmenorrhea.
<시험예 2> 비만인에 대한 생리통 완화 및 치료 효능 평가Experimental Example 2 Evaluation of Menstrual Pain Relief and Treatment Efficacy in Obese People
통상의 방법에 따라 시험예 1의 검사자 31인의 체질을 평가하여, 정상인과 비만인으로 분류하고, 이들의 복용일수에 따른 생리통증 변화를 통상의 방법에 따라 측정하고, 그 결과를 도 1 및 도 2에서 그래프로 나타내었다. 측정은 통상의 문진(問診)의 방법에 의해 수행하였다. 도 1 및 도 2에서 알 수 있는 바와 같이, 생리통증은 보통체형 혹은 비만체형 여부에 상관없이 시간 경과에 따라 크게 감소하는 결과를 나타내었다. 예를 들어, 도 1 및 도 2에서, 본 발명의 한약조성물의 복용기간이 생리전 7일 동안인 경우(X축) 통증정도는 25% 정도 완화됨(Y축)을 알 수 있다. 이로부터, 본 발명에 따른 한약 조성물은 비만체질 여성의 원발성 생리통 치료에도 효과적임을 알 수 있다.According to a conventional method, the constitution of 31 test subjects of Test Example 1 was evaluated, classified into normal and obese persons, and the change in menstrual pain according to the days of their administration was measured according to a conventional method, and the results are shown in FIGS. 1 and 2. Shown in the graph The measurement was performed by a conventional method of paperweight. As can be seen in Figures 1 and 2, menstrual pain showed a significant decrease over time whether or not normal or obese. For example, in Figures 1 and 2, when the taking period of the herbal composition of the present invention for 7 days before menstruation (X-axis) it can be seen that the degree of pain is alleviated by 25% (Y-axis). From this, it can be seen that the herbal composition according to the present invention is also effective for treating primary dysmenorrhea in obese women.
다른 질환을 동시에 가진 여성의 경우라면, 그 질환 치료에 효능을 갖는 한약재를 본 발명의 한약 조성물에 더 추가할 수 있다. 예를 들어, 변비가 있는 환자의 경우 변비환을 추가하고, 수족냉증이 심한 환자의 경우 부자(附子)를 추가하며, 혈괴(血塊)가 심한 환자의 경우 귀전우(鬼箭羽)를 더 투여한다.In the case of a woman having another disease at the same time, it is possible to further add to the herbal composition of the present invention the herbal medicine that is effective in treating the disease. For example, add constipation in patients with constipation, add rich people in patients with severe cold hands and feet, and add more precious cows in patients with severe blood clots. do.
본 발명에 의하면 본 발명의 한약 조성물을 환제, 정제, 캡슐제, 액제, 건강식품, 건강음료 등과 같은 제형으로 제조하여 복용함으로써 대부분의 생리통 환자에게서 나타나는 아랫배 통증, 허리 통증, 부종, 두통 등의 생리통 증상을 우수하게 치료할 수 있다. 또한, 이러한 치료는 종래의 침구 치료와 병행하여 사용할 수 있다.According to the present invention by taking the herbal composition of the present invention in the form of a pill, tablets, capsules, liquids, health foods, health beverages, and the like by taking the menstrual pain, such as belly pain, back pain, swelling, headache that appear in most menstrual pain patients The symptoms can be treated well. In addition, such treatments can be used in combination with conventional bedding treatments.
이상에서 본 발명은 기재된 구체예에 대해서만 상세히 설명되었지만 본 발명의 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속함은 당연한 것이 다.Although the present invention has been described in detail only with respect to the described embodiments, it will be apparent to those skilled in the art that various modifications and variations are possible within the technical spirit of the present invention, and such modifications and modifications belong to the appended claims. .
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070031630A KR100912912B1 (en) | 2007-03-30 | 2007-03-30 | Herbal composition for relieving and treating primary dysmenorrhea |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070031630A KR100912912B1 (en) | 2007-03-30 | 2007-03-30 | Herbal composition for relieving and treating primary dysmenorrhea |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080088834A KR20080088834A (en) | 2008-10-06 |
KR100912912B1 true KR100912912B1 (en) | 2009-08-20 |
Family
ID=40150799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070031630A KR100912912B1 (en) | 2007-03-30 | 2007-03-30 | Herbal composition for relieving and treating primary dysmenorrhea |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100912912B1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102370795B (en) * | 2011-10-16 | 2013-08-14 | 广东养美医药投资有限公司 | Self-heated traditional Chinese medicine (TCM) emplastrum for treating primary dysmenorrhea |
CN102343009B (en) * | 2011-10-18 | 2013-09-18 | 刘运波 | Traditional Chinese medicine for treating dysmenorrhea |
CN102441088B (en) * | 2011-11-30 | 2014-04-02 | 宋爱民 | Traditional Chinese medicinal liquor used for treating lumbar muscle fiber inflammation |
CN102614489A (en) * | 2012-04-24 | 2012-08-01 | 潍坊诺达药业有限公司 | Medicinal composition for treating renal edema of livestock and poultry and preparation method for medicinal composition |
CN102861148B (en) * | 2012-10-19 | 2014-04-02 | 天津中医药大学 | Chinese medicine preparation for treating primary dysmenorrheal and preparation method and application |
CN102895348B (en) * | 2012-11-08 | 2014-07-30 | 成都中医药大学 | Pharmaceutical compositions for treating rheumatic joint disease, preparation method thereof and use thereof |
CN104056039A (en) * | 2014-06-23 | 2014-09-24 | 张玉雯 | Contraction-inducing and nourishing soup and preparation method thereof |
CN104288747A (en) * | 2014-10-31 | 2015-01-21 | 赵清玲 | Traditional Chinese medicine preparation used for curing dysmenorrhea |
CN104491375A (en) * | 2014-12-08 | 2015-04-08 | 成都锦汇科技有限公司 | Health granules for conditioning physical health of women |
CN104587426A (en) * | 2014-12-25 | 2015-05-06 | 武海波 | Traditional Chinese medicine composition capable of dispelling cold in warmness |
CN104491746B (en) * | 2015-01-06 | 2017-11-03 | 唐萍 | It is a kind of to treat traditional Chinese medicine oral liquid of irregular menstruation and preparation method thereof |
CN104547755A (en) * | 2015-01-23 | 2015-04-29 | 王士金 | Blood-enriching and wind-expelling medicine for postpartum fever and preparation |
CN104666922A (en) * | 2015-03-27 | 2015-06-03 | 臧兰恕 | Chinese medicinal composition for treating irregular menstruation due to deficiency of qi in spleen and kidney |
CN104840824A (en) * | 2015-06-01 | 2015-08-19 | 徐艳 | Medicine preparation for treating cervicitis |
CN104940630A (en) * | 2015-07-04 | 2015-09-30 | 窦欣欣 | Traditional Chinese medicine composition for treating qi and blood deficiency type menstrual body pain |
CN105012636A (en) * | 2015-08-07 | 2015-11-04 | 李强 | Traditional Chinese medicine composition for treating dysmenorrhea |
CN105148086A (en) * | 2015-10-16 | 2015-12-16 | 烟台瑞智生物医药科技有限公司 | Traditional Chinese medicine composition for treating dysmenorrheal caused by asthenia of qi and blood |
CN105148088A (en) * | 2015-10-16 | 2015-12-16 | 烟台瑞智生物医药科技有限公司 | Traditional Chinese medicine composition for treating dysmenorrheal caused by yang deficiency and internal cold |
CN105148026A (en) * | 2015-10-16 | 2015-12-16 | 烟台瑞智生物医药科技有限公司 | Traditional Chinese medicine composition for treating dysmenorrheal caused by damp-heat stagnation |
CN105288151A (en) * | 2015-10-20 | 2016-02-03 | 蔡树正 | Chinese herbal medicine composition having effects of improving woman health, protecting activity, keeping young and maintaining beauty |
CN107029184B (en) * | 2017-04-28 | 2018-04-17 | 北京市永康年健康科技有限责任公司 | A kind of mangosteen turmeric product and its preparation method and application |
CN108096492A (en) * | 2017-12-29 | 2018-06-01 | 湖南三五二环保科技有限公司 | A kind of pharmaceutical composition pill for treating dysmenorrhoea and its processing method |
KR102145347B1 (en) * | 2018-12-11 | 2020-08-19 | 주식회사 제넨셀 | Composition for improving premenstrual syndrome symptom comprising extract of Aucklandiae radix |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020087572A (en) * | 2001-05-14 | 2002-11-23 | (주)뉴로타이드 | East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof |
KR20050004950A (en) * | 2003-06-27 | 2005-01-13 | (주) 한약마을 | Composition comprising the herbal complex extract for prevention and treatment of menorrhalgia and dysmenorrhea |
-
2007
- 2007-03-30 KR KR1020070031630A patent/KR100912912B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020087572A (en) * | 2001-05-14 | 2002-11-23 | (주)뉴로타이드 | East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof |
KR20050004950A (en) * | 2003-06-27 | 2005-01-13 | (주) 한약마을 | Composition comprising the herbal complex extract for prevention and treatment of menorrhalgia and dysmenorrhea |
Also Published As
Publication number | Publication date |
---|---|
KR20080088834A (en) | 2008-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100912912B1 (en) | Herbal composition for relieving and treating primary dysmenorrhea | |
KR20110109607A (en) | Composition of herb medicine for reliefing and curing lumbar disc pain | |
CN104740458A (en) | Pruritus treating traditional Chinese medicine composition | |
CN103705751B (en) | Chinese medicine composition being used for the treatment of lumbago due to pathogenic wind-dampness and preparation method thereof | |
CN106267120A (en) | A kind of Chinese medicine for treating rhinitis preparation and preparation method thereof | |
KR20240102982A (en) | Traditional Chinese herbal medicine for the treatment of hives, eczema, allergies/kinetic reactive constitution | |
CN110898201B (en) | A topical Chinese medicinal composition for removing food stagnation in children, and its preparation method | |
CN1319403A (en) | Medicine for treating allergic purpura | |
CN103330888B (en) | Cleaning fluid for treatment of pruritus vulvae | |
CN105012430A (en) | Sciatica treating medicine and preparation method thereof | |
CN104888081A (en) | Instant herbal medicine for treating kidney-yang deficiency type diarrhea associated with menstruation | |
CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
CN100415288C (en) | A Chinese traditional medicinal preparation for treatment of psoriasis | |
CN103191330A (en) | Traditional Chinese medicine used for treating swelling of limbs of hemiplegic patient | |
CN106266131A (en) | A kind of for medicine for external application treating eczema and preparation method thereof | |
CN105617322A (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
CN104436109A (en) | Traditional Chinese medicine preparation for treating scleroderma | |
CN104435641A (en) | Traditional Chinese medicine preparation for treating hyperthyroidism | |
CN104352667A (en) | Medicine for treating nonspecific vaginitis and preparation method | |
CN104353043A (en) | Traditional Chinese medicine composition for treating dawn diarrhea and preparation method thereof | |
CN109847020A (en) | It is a kind of for gynaecological imflammation, the Chinese medicine composition of koro and its preparation method and application | |
CN100546607C (en) | The leukodermic Chinese medicine preparation of a kind of treatment | |
CN106256371A (en) | A kind of Chinese medicine composition treating blood stasis type abdominal mass and preparation method thereof | |
CN106362084B (en) | Dong's medicine for preventing gynecological diseases | |
CN103989837A (en) | Traditional Chinese medicine composition for preventing and treating haemorrhoids and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
E801 | Decision on dismissal of amendment | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |